Effect of anti-EPCR antibody and PAR-1 inhibitor on APC-mediated suppression of allergic inflammation. Different pairs of primers (Table 1) were used for amplification of mouse (179 bp) and human EPCR (279 bp). (A) Murine lymphocytes, U-937 cells, and HeLa cells expressed EPCR mRNA, as demonstrated by RT-PCR. (B) Pretreatment of mice with intravenous injection (OVA + APC + iv-anti-EPCR) or inhalation (OVA + APC + inh-anti-EPCR) of antimouse EPCR significantly blocked APC-induced decreases in BALF eosinophilic counts. Inhalation of PAR-1 inhibitor exerted no effect on APC suppressive activity. (C) APC-mediated inhibition of IL-4 was also significantly decreased by anti-EPCR antibody in spleen lymphocytes. (D) Total protein level in BALF from OVA-sensitized mice treated with inhaled PC (OVA + PC) was not significantly different from that in OVA-sensitized mice treated with inhaled saline (OVA + SAL). Data represent the mean ± SD of 12 measurements from 2 separate experiments. *P < .05, compared with OVA + SAL or OVA alone group; **P < .05, compared with the SAL and OVA (–) group; ¶P < .05, compared with the OVA + APC + SAL group.